Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Bruce Jackson
BENC
Bruce Jackson
Wall Street Analyst
★☆☆☆☆
#2566
on 13Foresight · ranked by our own returns
32%
Success Rate
-19.2%
Average Return
11 of 34 calls profitable · -31.8% vs benchmark
📈 Across the calls we could measure, roughly 32% of Bruce Jackson's ratings turned a profit when each position was held for 1 year — averaging -19.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

50 Buy 7 Hold 0 Sell
Bruce's Stock Coverage 40 ratings · 2026-06-19
Company Date Position Consensus Price Target 1-Yr Return
MMED
MiniMed Group, Inc.
Jun 03, 2026 BUY Strong Buy
+48.5% avg upside
13 analysts
$20.00
35.48% Upside
·
UNCY
Unicycive Therapeutics
Jun 02, 2026 BUY Strong Buy
+708.7% avg upside
10 analysts
$18.00
162.73% Upside
·
HUMA
Humacyte
Jun 01, 2026 BUY Strong Buy
+654.7% avg upside
11 analysts
$2.00
116.35% Upside
-27.2%
BFRI
Biofrontera
May 19, 2026 BUY Strong Buy
+507.8% avg upside
2 analysts
$3.00
203.86% Upside
-1.4%
PODD
Insulet
May 12, 2026 BUY Strong Buy
+79.3% avg upside
32 analysts
$250.00
71.58% Upside
-5.5%
DXCM
Dexcom
May 11, 2026 BUY Strong Buy
+38.8% avg upside
32 analysts
$77.00
6.18% Upside
+23.3%
TNDM
Tandem Diabetes Care
May 11, 2026 HOLD Buy
+115.3% avg upside
29 analysts
+14.4%
NEO
NeoGenomics
Apr 29, 2026 BUY Strong Buy
+40.2% avg upside
17 analysts
$11.00
1.25% Downside
+24.4%
ABT
Abbott Laboratories
Apr 17, 2026 BUY Strong Buy
+31.2% avg upside
35 analysts
$120.00
35.66% Upside
-8.6%
CV
CapsoVision, Inc.
Mar 27, 2026 BUY Strong Buy
+36.2% avg upside
3 analysts
$10.00
51.34% Upside
-14.8%
GNLX
Genelux Corp.
Mar 20, 2026 BUY Strong Buy
+513.8% avg upside
7 analysts
$20.00
574.54% Upside
+26.7%
HBIO
Harvard Bioscience
Mar 16, 2026 BUY Strong Buy
+160.0% avg upside
3 analysts
$6.00
2.17% Upside
+10.2%
BLTE
Belite Bio, Inc. ADR
Mar 03, 2026 BUY Strong Buy
+25.0% avg upside
10 analysts
$217.00
48.47% Upside
-17.7%
CLNN
Clene
Dec 03, 2025 BUY Strong Buy
+442.4% avg upside
11 analysts
$31.00
415.82% Upside
-5.3%
MLSS
Milestone Scientific
Nov 20, 2025 BUY Strong Buy
+169.3% avg upside
2 analysts
$1.00
169.30% Upside
-9.7%
SKIN
Beauty Health
Nov 07, 2025 HOLD Hold
+408.7% avg upside
11 analysts
-54.3%
VNRX
VolitionRX
Sep 15, 2025 HOLD Strong Buy
+589.8% avg upside
11 analysts
-81.9%
RVPH
Reviva Pharmaceuticals Holdings
Sep 15, 2025 BUY Strong Buy
+7085.8% avg upside
9 analysts
$140.00
22850.85% Upside
-91.7%
MOVE
Movano
Apr 24, 2025 BUY Strong Buy
+33.2% avg upside
4 analysts
$30.00
33.21% Upside
+167.2%
MODD
Modular Medical
Nov 26, 2024 BUY Strong Buy
+56.6% avg upside
3 analysts
$8.00
55.34% Upside
-75.9%
RKTO
Rocket One
Oct 11, 2024 BUY Strong Buy
+905.3% avg upside
8 analysts
$3.00
177.85% Upside
·
CDIO
Cardio Diagnostics Holdings
Jun 06, 2024 BUY Strong Buy
+152.6% avg upside
2 analysts
$2.00
1.09% Upside
-76.7%
TNON
Tenon Medical, Inc.
Apr 15, 2024 BUY Strong Buy
+2685.7% avg upside
3 analysts
$24.00
6757.23% Upside
-80.5%
USBC
USBC
Apr 08, 2024 BUY Buy
+139.0% avg upside
2 analysts
$1.00
138.96% Upside
·
BIOLQ
BIOLASE
Mar 22, 2024 BUY Strong Buy
+1197999900.0% avg upside
6 analysts
$0.40
39999899.94% Upside
·
SEELQ
Seelos Therapeutics
Sep 21, 2023 BUY Buy
+46385614.3% avg upside
10 analysts
$240.00
239999899.98% Upside
-99.6%
STAA
Staar Surgical
Sep 15, 2023 HOLD Hold
+14.3% avg upside
16 analysts
-25.3%
IMDX
Insight Molecular Diagnostics
Aug 24, 2023 BUY Buy
-0.6% avg upside
10 analysts
$5.00
8.10% Downside
·
GDTC
CytoMed Therapeutics Limited
Jul 21, 2023 BUY Strong Buy
+354.5% avg upside
1 analyst
$5.00
354.52% Upside
·
HSCS
Heart Test Laboratories, Inc.
Mar 23, 2023 BUY Strong Buy
+334.8% avg upside
3 analysts
$4.00
117.31% Upside
-88.3%
ORGS
Orgenesis
Mar 22, 2023 BUY Strong Buy
+1784.4% avg upside
1 analyst
$6.00
1784.36% Upside
·
CNSP
CNS Pharmaceuticals
Jun 29, 2021 BUY Strong Buy
+495.7% avg upside
5 analysts
$8.00
70.14% Upside
-87.1%
SNOA
Sonoma Pharmaceuticals
Jul 20, 2018 BUY Buy
+1755.0% avg upside
4 analysts
$27.00
2247.74% Upside
-71.5%
HRTX
Heron Therapeutics
Apr 05, 2018 BUY Strong Buy
+6439.5% avg upside
21 analysts
$42.00
9959.79% Upside
-6.5%
AXGN
AxoGen
Mar 02, 2018 BUY Strong Buy
-25.8% avg upside
21 analysts
$38.00
15.18% Downside
-41.5%
MDXG
MiMedx Group
Feb 26, 2018 HOLD Strong Buy
+185.0% avg upside
17 analysts
-58.9%
LCTX
Lineage Therap
Feb 02, 2018 BUY Strong Buy
+342.7% avg upside
16 analysts
$8.00
561.10% Upside
·
IART
Integra Lifesciences
Oct 28, 2016 BUY Buy
+137.0% avg upside
21 analysts
$92.00
423.26% Upside
+13.4%
MDT
Medtronic
Nov 21, 2012 HOLD Buy
+23.7% avg upside
38 analysts
$46.00
42.10% Downside
+36.6%
BSX
Boston Scientific
Mar 02, 2012 BUY Strong Buy
+73.0% avg upside
38 analysts
+22.8%
🔒 35 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Bruce Jackson — Frequently Asked Questions
How accurate are Bruce Jackson's stock ratings?
Based on the calls 13Foresight could measure, about 32% of Bruce's ratings were profitable over a one-year hold, with an average return of -19.2% per rating, or -31.3% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Bruce ranked on 13Foresight?
Bruce Jackson is currently ranked #2566 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Bruce cover?
Bruce most recently has ratings on MMED, UNCY, HUMA, BFRI, PODD, DXCM, TNDM, NEO, ABT, CV, GNLX, HBIO and 28 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.